Chest radiation to treat Wilms tumor may increase risk for developing breast cancer
the ONA take:
According to a new study published online in the journal Cancer, children who underwent chest radiation for the treatment of Wilms tumor may have an increased risk for developing breast cancer in the future as a result of their radiation exposure.
Researchers at the Fred Hutchinson Research Cancer Center in Seattle, Washington, sought to investigate whether or not a child's radiation exposure affects her risk for developing breast cancer later in life. The team identified nearly 2,500 patients who had been treated for Wilms tumor, a rare childhood kidney cancer that can metastasize to the lungs, during their childhood and who had lived until at least age 15.
Of those, over 20% developed breast cancer, 75% of which were invasive and 25% were non-invasive, by age 40. Only 0.3% of patients who did not receive chest radiation went on to develop breast cancer. In addition, 4% of patients who received abdominal, but not chest, radiation for the treatment of their Wilms tumor developed breast cancer by age 40.
The results shows that females receiving chest radiation are 30 times more likely to develop breast cancer than those of comparable age in the general population.
Children who underwent chest radiation may have an increased risk for developing breast cancer.
A new study has found that patients who received chest radiation for Wilms tumor, a rare childhood cancer, face an increased risk of developing breast cancer later in life due to their radiation exposure. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the findings suggest that cancer screening guidelines might be re-evaluated to facilitate the early diagnosis and prompt treatment of breast cancer among Wilms tumor survivors.
Wilms tumor is a rare childhood kidney cancer that can spread to the lungs. When this spread occurs, patients receive a relatively low dose of 12-14 Gray of radiation therapy to the entire chest.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
- Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma
- Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|